Get the Stockscreener App
14.26
0.35%
0.05
Pre-market:
14.26
Wave Life Sciences Ltd stock is traded at $14.26, with a volume of 667.01K.
It is up +0.35% in the last 24 hours and down -6.86% over the past month.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$14.21
Open:
$14.23
24h Volume:
667.01K
Relative Volume:
0.38
Market Cap:
$2.17B
Revenue:
$113.31M
Net Income/Loss:
$-57.51M
P/E Ratio:
-10.49
EPS:
-1.36
Net Cash Flow:
$-20.55M
1W Performance:
-9.11%
1M Performance:
-6.86%
6M Performance:
+123.51%
1Y Performance:
+174.23%
1-Day Range:
$13.86
$14.49
1-Week Range:
$12.66
$16.08
52-Week Range:
$3.50
$16.73
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| WVE | 14.26 | 2.17B | 113.31M | -57.51M | -20.55M | -1.36 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-27-24 | Resumed | JP Morgan | Overweight |
| Sep-19-24 | Initiated | B. Riley Securities | Buy |
| Sep-09-24 | Initiated | JP Morgan | Overweight |
| May-15-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Raymond James | Outperform |
| May-24-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Jul-15-19 | Initiated | Cowen | Market Perform |
| Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-07-18 | Initiated | Stifel | Buy |
| Jul-23-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Reiterated | Mizuho | Buy |
| Feb-15-17 | Initiated | H.C. Wainwright | Buy |
| Nov-10-16 | Resumed | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
| Dec-07-15 | Initiated | Jefferies | Buy |
| Dec-07-15 | Initiated | Leerink Partners | Outperform |
| Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Wave Life Sciences Advances RNA Medicine Innovations - TipRanks
B. Riley Cuts Earnings Estimates for Wave Life Sciences - MarketBeat
HC Wainwright Has Pessimistic Outlook of WVE FY2024 Earnings - MarketBeat
Trading (WVE) With Integrated Risk Controls - Stock Traders Daily
Insider Sale: President and CEO Paul Bolno Sells 51,234 Shares o - GuruFocus.com
Wave Life Sciences Ltd. (NASDAQ:WVE) CEO Sells $733,670.88 in Stock - MarketBeat
Wave Life Sciences CEO Paul Bolno sells shares for $733,670 By Investing.com - Investing.com UK
Wave Life Sciences CEO Paul Bolno sells shares for $733,670 - Investing.com India
WVEWave Life Sciences Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
What is HC Wainwright's Forecast for WVE FY2028 Earnings? - MarketBeat
Wave Life Sciences to Present at Jefferies London Healthcare Conference - The Manila Times
What is B. Riley's Estimate for WVE Q1 Earnings? - MarketBeat
US$22.20That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results - Simply Wall St
Wave Life Sciences Ltd. (NASDAQ:WVE) Released Earnings Last Week And Analysts Lifted Their Price Target To US$22.20 - Yahoo Finance
Leerink Partnrs Has Bullish Forecast for WVE FY2024 Earnings - MarketBeat
Wave Life Sciences Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St
Wave Life Sciences Ltd. (NASDAQ:WVE) Short Interest Update - MarketBeat
WaVe Life Sciences's SWOT analysis: RNA editing stock faces pivotal year - Investing.com
Wave Life Sciences executive sells shares worth $576,000 By Investing.com - Investing.com Nigeria
Wave Life Sciences executive sells shares worth $576,000 - Investing.com India
Earnings call: Wave Life Sciences outlines transformative 2025 outlook By Investing.com - Investing.com Australia
Alpha-1 Antitrypsin Deficiency Market Expected to Experience Major Growth by 2034, According to DelveInsight | Kamada Pharma, Mereo BioPharma/AstraZeneca, Grifols Therapeutics LLC, Takeda, Vertex - Barchart
Wave Life Sciences (NASDAQ:WVE) Given "Buy" Rating at HC Wainwright - MarketBeat
Wave Life Sciences Ltd. (NASDAQ:WVE) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Wave Life Sciences outlines transformative 2025 outlook - Investing.com
WAVE Life Sciences Ltd (WVE) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Wave Life Sciences’ Q3 2024 Advances in RNA Therapies - TipRanks
Wave Life Sciences: Q3 Earnings Snapshot - CT Insider
Wave Life Sciences Ltd earnings missed by $0.19, revenue fell short of estimates - Investing.com Nigeria
Wave Life Sciences price target raised to $36 from $17 at Truist - TipRanks
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates - MSN
Wave Life Sciences files automatic mixed securities shelf - TipRanks
Q3 2024 WAVE Life Sciences Ltd Earnings Call Transcript - GuruFocus.com
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Wave Life Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Wave Life Sciences Achieves First-Ever Human RNA Editing, Reports $310.9M Cash Position | WVE Stock News - StockTitan
WAVE Life Sciences Ltd (WVE) Q3 2024: Everything You Need to Kno - GuruFocus.com
Privium Fund Management B.V. Purchases Shares of 48,834 Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences (NASDAQ:WVE) Reaches New 12-Month HighStill a Buy? - MarketBeat
Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking - Simply Wall St
WVE stock surges to 52-week high, touches $15.99 amid robust gains - Investing.com Australia
Wave Life Sciences treatment of Huntington’s disease gets FDA orphan designation - TipRanks
(WVE) On The My Stocks Page - Stock Traders Daily
Wave Life Sciences (WVE) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Wave Life Sciences (WVE) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024 - StockTitan
B. Riley Issues Positive Forecast for Wave Life Sciences (NASDAQ:WVE) Stock Price - MarketBeat
Institutional investors in Wave Life Sciences Ltd. (NASDAQ:WVE) see US$94m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Emerald Advisers LLC Boosts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):